Objectives: Our primary objective was to determine the response rate; secondary objectives were to assess the toxicity rate, and disease-free and overall survival rates in patients with locally advanced breast cancer (LABC) receiving a cyclophosphamide (500 mg/m2), mitoxantrone (12 mg/m2) and 5-fluorouracil (500 mg/m2) (CMF) chemotherapy regimen.
Patients And Methods: The data from 74 patients with LABC with neoadjuvant CMF chemotherapy were analyzed retrospectively. Preoperatively, all patients received 3 cycles of CMF on day 1, repeated every 21 days. In 3 (4.1%) patients, breast-conserving surgery was given and in 71 (95.9%) modified radical mastectomy. All patients received radiotherapy and 3 additional cycles of CMF chemotherapy after surgery.
Results: Median age of the patients was 47 years (range: 17-74). 43 patients were premenopausal, whereas 31 were postmenopausal. 54 patients were in stage IIIA, and 20 were in stage IIIB. The overall clinical response rate was 88%; 11 (14.9%) had a complete response, 54 (73%) had a partial response, and 2 (2.8%) had progression. 14 (18.9%) had a pathological complete response. The median follow-up was 62 months. The median disease-free survival was 64.9 months, and the median overall survival was 97.5 months. The 5-year disease-free and overall survival rates were 52% and 79.9%, respectively. Most frequent side-effects were nausea/vomiting, mucositis, alopecia and leukopenia.
Conclusion: The CMF regimen has a high overall response rate and an acceptable side effect profile in the treatment of locally advanced breast cancer. Further studies are needed to evaluate its effectiveness in breast-conserving strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1159/000082951 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Aerolysin Nanopore Electrochemistry.
Acc Chem Res
January 2025
Molecular Sensing and Imaging Center, School of Chemistry and Chemical Engineering, Nanjing University, Nanjing 210023, China.
ConspectusIons are the crucial signaling components for living organisms. In cells, their transportation across pore-forming membrane proteins is vital for regulating physiological functions, such as generating ionic current signals in response to target molecule recognition. This ion transport is affected by confined interactions and local environments within the protein pore.
View Article and Find Full Text PDFInavolisib: First Approval.
Drugs
January 2025
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Inavolisib (Itovebi) is an orally administered, phosphatidylinositol-3-kinase alpha (PI3Kα) inhibitor being developed by Genentech, a member of the Roche group, for the treatment of solid tumours. On 10 October 2024, inavolisib received its first approval in the USA in combination with palbociclib and fulvestrant for the treatment of adults with endocrine-resistant, PIK3CA-mutated, hormone receptor (HR)-positive, human epidermal growth factor 2 (HER2)-negative, locally advanced or metastatic breast cancer, as detected by an FDA-approved test, following recurrence on or after completing adjuvant endocrine therapy. In the EU and other countries worldwide, regulatory review of inavolisib is currently underway.
View Article and Find Full Text PDFGenetics of sorghum: grain quality, molecular aspects, and drought responses.
Planta
January 2025
Department of Plant Sciences, University of the Free State, Bloemfontein, South Africa.
Sorghum kernel composition is a crucial characteristic that determines its functional qualities. The total protein content of sorghum grain increases under drought stress, but starch, protein digestibility, and micronutrient contents decrease. Sorghum (Sorghum bicolor L.
View Article and Find Full Text PDFOpen-Source Large Language Models in Radiology: A Review and Tutorial for Practical Research and Clinical Deployment.
Radiology
January 2025
From the University of Maryland Medical Intelligent Imaging (UM2ii) Center, Department of Diagnostic Radiology and Nuclear Medicine, University of Maryland School of Medicine, 22 S Greene St, Baltimore, MD 21201 (C.H.S., A.K., V.P., F.X.D.); Departments of Radiology, Medicine, and Biomedical Data Science, Stanford University, Palo Alto, Calif (C.P.L.); Department of Computer Science and Electrical Engineering, College of Engineering and Information Technology, University of Maryland, Baltimore County, Baltimore, Md (A.J.); Department of Computer Science, University of Maryland, College Park, College Park, Md (H.H.); and University of Maryland Institute for Health Computing, University of Maryland, North Bethesda, Md (H.H., F.X.D.).
Integrating large language models (LLMs) into health care holds substantial potential to enhance clinical workflows and care delivery. However, LLMs also pose serious risks if integration is not thoughtfully executed, with complex challenges spanning accuracy, accessibility, privacy, and regulation. Proprietary commercial LLMs (eg, GPT-4 [OpenAI], Claude 3 Sonnet and Claude 3 Opus [Anthropic], Gemini [Google]) have received much attention from researchers in the medical domain, including radiology.
View Article and Find Full Text PDFVirtual Reality-Based Attention Prediction Model in Gaming for Autistic Children.
Int J Dev Neurosci
February 2025
Department of Computer Science and Engineering, Vels Institute of Science & Technology & Advanced Studies, Chennai, Tamilnadu, India.
Nowadays, virtual reality (VR) has emerged as a successful new therapeutic strategy in a variety of sectors of the health profession, including rehabilitation, the promotion of inpatients' emotional wellness, diagnostics, surgeon training and mental health therapy. This study develops a new model VRAPMG for children with ASD with the following steps that consider 3D gaming. In this work, the face image is considered to evaluate the attention of the children.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!